Benlysta and Osteomyelitis - a phase IV clinical study of FDA data

Summary:

Osteomyelitis is reported as a side effect among people who take Benlysta (belimumab), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Plaquenil, and have Quit smoking.

The phase IV clinical study analyzes which people have Osteomyelitis when taking Benlysta. It is created by eHealthMe based on reports of 23,452 people who have side effects when taking Benlysta from the FDA, and is updated regularly.

What is Benlysta?

Benlysta has active ingredients of belimumab. It is often used in systemic lupus erythematosus. eHealthMe is studying from 23,528 Benlysta users. Check the latest studies of Benlysta.

What is Osteomyelitis?

Osteomyelitis (infection of bone) is found to be associated with 1,430 drugs and 1,327 conditions by eHealthMe. Check the latest studies of Osteomyelitis.

On Jun, 17, 2026

23,452 people reported to have side effects when taking Benlysta.
Among them, 21 people (0.09%) have Osteomyelitis.

Among these 21 people:

How long have people been on Benlysta when they have Osteomyelitis? *

What is the gender of people who have Osteomyelitis when taking Benlysta? *

female: 95 %
male: 5 %

What is the age of people who have Osteomyelitis when taking Benlysta? *

What are other drugs people take besides Benlysta? *

What are other side effects people have besides Osteomyelitis? *

Fatigue (feeling of tiredness): 7 people, 33.33%
Weakness: 6 people, 28.57%
Insomnia (sleeplessness): 6 people, 28.57%
Drowsiness: 5 people, 23.81%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 23.81%
Hair Loss: 5 people, 23.81%
Exfoliative Rash (scaly red generalized skin rash): 5 people, 23.81%
Drug Ineffective: 5 people, 23.81%
Pain In Extremity: 4 people, 19.05%
Procedural Complication: 4 people, 19.05%

What are the existing conditions these people have? *

Quit Smoking: 2 people, 9.52%
Osteoporosis (bones weak and more likely to break): 1 person, 4.76%
Metastases To Prostate (cancer spreads to prostate): 1 person, 4.76%
Metastases To Bone (cancer spreads to bone): 1 person, 4.76%
Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Benlysta and have Osteomyelitis?

- Check whether Osteomyelitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Benlysta:

Benlysta (23,528 reports)

Osteomyelitis treatments and more:

Osteomyelitis (34,172 reports)

Browse all side effects of Benlysta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteomyelitis:

Osteomyelitis (1,430 drugs)

Browse all the conditions that are associated with Osteomyelitis:

Osteomyelitis (1,327 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on belimumab (the active ingredients of Benlysta) and Benlysta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.